Replies to post #86233 on Biotech Values

[DewDiligence]

why would genotype 2/3s still be treated 48 weeks once their is a direct anti-viral on the market? Unless you are referring to the fact that the G2/3 trials are lagging?

Geno-2/3 patients have been harder to cure than geno-1/4 patients for any drug regimen I know of that’s been tried against all of the HCV genotypes. Moreover, among the three main classes of direct antivirals, only the nukes offer pan-genotypic coverage; by and large, the non-nukes and protease inhibitors in development today have been tailored for genotype 1.

[DewDiligence]

Please ignore the part of my post pertaining to geno-2/3 patents—that was a brain cramp. The part of my post about 48 weeks of treatment for non-RVR patients stands, as does the main point of this thread (#msg-43559034).